Published by Benjamin Chiou on 27th September 2024
(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health has announced that the schizophrenia treatment it developed, which was later sold to Bristol Myers Squibb, has been approved by US regulators, triggering milestone payment and unlocking potential future royalties.